FMP
F-star Therapeutics, Inc.
FSTX
NASDAQ
Inactive Equity
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
7.12 USD
0 (0%)
We are unable to load the chart at this time.
We are unable to load the chart at this time.
Date
Revenue
Earnings
Estimated Earnings
Surprise
2023-05-08
0
0
-0.39
-
2023-03-22
0
0.47
-0.39
-220.51%
2022-11-10
1.13M
-0.84
-0.79
6.33%
2022-08-11
0
-0.88
-0.58
51.72%
2022-05-10
2.55M
-0.57
-0.67
-14.93%
2022-03-14
17.5M
0.48
-0.11
-536.36%
2021-11-10
751k
-0.52
-0.58
-10.34%
2021-08-12
0
-0.92
-0.74
24.32%
2021-05-17
2.92M
-1.08
-1.16
-6.90%
2020-12-31
163k
-0.5
0
-
2020-11-03
9.2M
-1.24
-1
24.00%
2020-08-10
543k
-1.52
-1.44
5.56%
2020-05-07
1.35M
-1.96
-0.8
145.00%
2020-02-14
0
-1.8
-2.68
-32.84%
2019-11-07
0
-1.68
-2.43
-30.86%
2019-07-31
0
-1.12
-2.22
-49.55%
2019-04-29
0
-1.28
-2.09
-38.76%
2019-03-11
0
-1.36
-2.26
-39.82%
2018-10-25
0
-0.59
-0.61
-3.28%
2018-08-01
0
-0.29
-0.53
-45.28%
2018-04-27
0
-0.37
-0.57
-35.09%
2018-02-20
0
-0.11
-0.54
-79.63%
2017-10-31
0
-0.85
-0.49
73.47%
2017-07-31
0
-0.93
-0.45
106.67%
2017-04-28
0
-0.69
-0.47
46.81%
2017-02-15
0
-0.21
-0.65
-67.69%
2016-10-31
0
-0.53
0
-
2016-08-01
0
-0
0
-
2016-05-11
0
-0
0
-